Inovio Pharmaceuticals
NYSE/NASDAQ:INOPharmaPlymouth, Pennsylvania, United States · Est. 1983 · 300 employees
Inovio Pharmaceuticals is a biotechnology company developing DNA-based immunotherapies and vaccines for cancer and infectious diseases.
0
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
0
Indications↗
Distinct diseases across all programs
29
Clinical Trials↗
All sponsored trials (all statuses)
Activity
Recent Activity
Last 14 days
Nov 2, 2026
8-K
8-K
Oct 23, 2026
Active, not recruiting
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Earlier
Oct 6, 20268-K8-K
Sep 3, 2026TrialAn Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Aug 12, 20268-K8-K
Jul 31, 20268-K8-K
Jul 29, 20268-K8-K
May 20, 20268-KINOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
4 more events
Oct 1, 2022TrialSafety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
Jun 21, 2021TrialSafety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
Jan 27, 2021TrialDose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
Nov 30, 2020TrialSafety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Details
Company Info
Company Overview
$150.0M
Mkt Cap
$40.6M
Revenue
$65.8M
Cash
CEOPeter Lis
Founded1983
Employees300
HQPlymouth, Pennsylvania, United States
ExchangeNYSE/NASDAQ:INO
Websiteinovio.com
LinkedInCompany Page
Therapeutic Focus
Other
Recent SEC Filings
8-KNov 2, 2026
8-K
8-KOct 6, 2026
8-K
8-KAug 12, 2026
8-K
8-KJul 31, 2026
8-K
8-KJul 29, 2026
8-K
Regulatory
Regulatory Timeline
20266 events
SECNov 2
8-K
Accession: 0001193125-26-442648
SECOct 6
8-K
Accession: 0001193125-26-415555
SECAug 12
8-K
Accession: 0001055726-26-000024
SECJul 31
8-K
Accession: 0001193125-26-326785
SECJul 29
8-K
Accession: 0001193125-26-323628
SECMay 20
INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Accession: 001-14888
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)